Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615000403538
Ethics application status
Approved
Date submitted
7/04/2015
Date registered
30/04/2015
Date last updated
18/12/2017
Type of registration
Retrospectively registered

Titles & IDs
Public title
Randomized Control Trial of Meropenem versus Piperacillin-Tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia Coli and Klebsiella species.
Scientific title
Randomized Control Trial of Meropenem versus Piperacillin-Tazobactam on mortality and clinial response in patients with bloodstream infections due to ceftriaxone non-susceptible Escherichia Coli and Klebsiella species.
Secondary ID [1] 286481 0
Nil
Universal Trial Number (UTN)
Trial acronym
MERINO
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Escherichia Coli blood infection 294672 0
Klebsiella species blood infection 294776 0
Condition category
Condition code
Infection 294977 294977 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Recruited participants will randomly be assigned to either receive the study drugs of Meropenem or Piperacillin-Tazobactam in a 1:1 ratio according to a randomisation list prepared in advance. The intervention treatment for this study is the administration of the drug Piperacillin-Tazobactam 4.5 grams administered every 6 hours intravenously over a 30 minute period. The duration of treatment with this drug will be for a minimum of 4 days and a maximum of 14 days. The duration of the therapy will be determined by the treating clinician.
Intervention code [1] 291571 0
Treatment: Drugs
Comparator / control treatment
The control treatment for this study is the administration of the drug Meropenem 1 gram to be administered every 8 hours intravenously over a 30 minute period. The duration of treatment with this drug will be for a minimun of 4 days and a maximum of 14 days. The duration of the therapy will be determined by the treating clinician.
Control group
Active

Outcomes
Primary outcome [1] 294729 0
1. The primary outcome for the trial is the occurence and confirmation of mortality at 30 days after the first positive blood culture.
Timepoint [1] 294729 0
30 days post first positive blood culture.
Secondary outcome [1] 313938 0
1. Time to clinical and microbiologic resolution.
Timepoint [1] 313938 0
Number of days from initiation of study drug to resolution of SIRS PLUS sterilisation of blood cultures.
Secondary outcome [2] 313939 0
2. Clinical and microbiologic success.
Timepoint [2] 313939 0
Survival at day four after the initation of study drug PLUS resolution of SIRS on or before day four PLUS sterilisation of blood cultures on or before day four.
Secondary outcome [3] 313940 0
3. Microbiologic resolution of infection.
Timepoint [3] 313940 0
Sterility of blood cultures on 3rd day post initial recruitment.
Secondary outcome [4] 313941 0
4. Microbiologic relapse.
Timepoint [4] 313941 0
Growth of the same organism as in the original blood culture after the end of the period of study drug administration, before 30 days after the first positive blood culture was drawn.

Eligibility
Key inclusion criteria
1. Bloodstream infection with Escherichia coli or Klebsiella spp., as defined by at least one positive blood culture from a peripheral blood draw.
2. Bacteria confirmed as ceftriaxone non-susceptible, Piperacillin-Tazobactam susceptible and Meropenem susceptible by use of EUCAST definitions (www.eucast.org).
3. No more than 72 hours since the first positive blood culture was collected for this infection.
4. Patient or their ethics committee approved proxy able to give written informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Patient not expected to survive more than 4 days.
2. Patient allergic to a penicillin or a carbapenem.
3. Patient with significant polymicrobial bacteraemia (that is, a Gram positive skin containment in one set of blood cultures is not regarded as significant polymicrobial bacteraemia).
4. Treatment is not with the intent to cure the infection (that is, palliative care is an exclusion).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Subjects who meet the inclusion criteria will be approached by the study team and given clear concise information about the trial in the form of verbal communication and a patient information form. Once the subject or their ethics committee approved proxy give written informed consent, they will be randomly assigned to receive either the study drugs of meropenem or piperacillin-tazobactam. Patients will be randomly assigned to either Meropeneum or Pipercillin-Tazobactam in a 1:1 ratio according to the randomisation list prepared in advance.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Recruited subjects will be randomly assigned to receive either meropenem or piperacillin/tazobactam in a 1:1 ratio according to a randomisation list prepared in advance (the radomisation list will be centrally radomised by a computer). Random sequence will be generated using random permuted blocks of unequal length. Four strata will be used. Subjects will be stratified according to the bacterial genus identified in the blood culture and the likelihood of death, as defined by the following high-risk features-any of: a) likely source of infection other than urinary or biliary tract, b) Pitt score greater than 4, c) presentation with severe sepsis or shock.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Data collected is being analysed
Reason for early stopping/withdrawal
Other reasons/comments
Other reasons
The study has been suspended due to the unlikeliness of the trial meeting the non-inferiority criteria.
Date of first participant enrolment
Anticipated
1/01/2015
Actual
16/04/2015
Date of last participant enrolment
Anticipated
31/12/2017
Actual
8/07/2017
Date of last data collection
Anticipated
Actual
8/07/2017
Sample size
Target
454
Accrual to date
Final
396
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA,VIC
Recruitment hospital [1] 3660 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [2] 3661 0
Westmead Hospital - Westmead
Recruitment hospital [3] 3662 0
The Alfred - Prahran
Recruitment hospital [4] 3663 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment hospital [5] 3664 0
Dandenong Hospital - Dandenong
Recruitment hospital [6] 3665 0
Wollongong Hospital - Wollongong
Recruitment hospital [7] 3666 0
Barwon Health - Geelong Hospital campus - Geelong
Recruitment hospital [8] 3667 0
Peter MacCallum Cancer Institute - East Melbourne
Recruitment hospital [9] 3668 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [10] 3669 0
Royal Perth Hospital - Perth
Recruitment hospital [11] 5037 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [12] 5038 0
Shellharbour Hospital - Mount Warrigal
Recruitment hospital [13] 5039 0
Mater Adult Hospital - South Brisbane
Recruitment postcode(s) [1] 9492 0
4029 - Royal Brisbane Hospital
Recruitment postcode(s) [2] 9493 0
2145 - Wentworthville
Recruitment postcode(s) [3] 9495 0
3168 - Clayton
Recruitment postcode(s) [4] 9497 0
2500 - Wollongong
Recruitment postcode(s) [5] 9498 0
3220 - Geelong
Recruitment postcode(s) [6] 9499 0
4102 - Woolloongabba
Recruitment postcode(s) [7] 9500 0
3002 - East Melbourne
Recruitment postcode(s) [8] 9501 0
6000 - Perth
Recruitment postcode(s) [9] 9533 0
3175 - Dandenong
Recruitment postcode(s) [10] 9534 0
3004 - Melbourne
Recruitment postcode(s) [11] 12523 0
6150 - Murdoch
Recruitment postcode(s) [12] 12524 0
2528 - Mount Warrigal
Recruitment postcode(s) [13] 12525 0
4101 - South Brisbane
Recruitment outside Australia
Country [1] 6790 0
New Zealand
State/province [1] 6790 0
Country [2] 6791 0
Singapore
State/province [2] 6791 0
Country [3] 7517 0
Italy
State/province [3] 7517 0
Country [4] 7518 0
South Africa
State/province [4] 7518 0
Country [5] 7519 0
Malaysia
State/province [5] 7519 0
Country [6] 7520 0
Canada
State/province [6] 7520 0
Country [7] 7521 0
Saudi Arabia
State/province [7] 7521 0
Country [8] 7522 0
Lebanon
State/province [8] 7522 0
Country [9] 7523 0
Turkey
State/province [9] 7523 0

Funding & Sponsors
Funding source category [1] 291047 0
Other Collaborative groups
Name [1] 291047 0
Australian Society for Infectious Diseases
Country [1] 291047 0
Australia
Funding source category [2] 291048 0
Other Collaborative groups
Name [2] 291048 0
Australian Society for Antimicrobials
Country [2] 291048 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Australasian Society of Infectious Diseases Clinical Research Network
Address
Suite 405, Level 4
5 Hunter Street
Sydney NSW 2000
Country
Australia
Secondary sponsor category [1] 289731 0
University
Name [1] 289731 0
University of Queensland Centre for Clinical Research
Address [1] 289731 0
Building 71/918 RBWH
Herston Rd
Herston QLD 4006
Country [1] 289731 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 292631 0
Royal Brisbane & Women's Hospital Human Research Ethics Committee
Ethics committee address [1] 292631 0
Ethics committee country [1] 292631 0
Australia
Date submitted for ethics approval [1] 292631 0
26/11/2012
Approval date [1] 292631 0
26/03/2013
Ethics approval number [1] 292631 0
HREC/12/RBWH/440

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 56322 0
Prof David L. Paterson
Address 56322 0
University of Queensland Centre for Clinical Research Level 8, 71/918 Royal Brisbane and Womens Hospital Herston Road Herston QLD 4029
Country 56322 0
Australia
Phone 56322 0
+61 7 3346 6074
Fax 56322 0
+61 7 3346 5598
Email 56322 0
david.antibiotics@gmail.com
Contact person for public queries
Name 56323 0
David L. Paterson
Address 56323 0
University of Queensland Centre for Clinical Research Level 8, 71/918 Royal Brisbane and Womens Hospital Herston Road Herston QLD 4029
Country 56323 0
Australia
Phone 56323 0
+61 7 3346 6074
Fax 56323 0
+61 7 3346 5598
Email 56323 0
david.antibiotics@gmail.com
Contact person for scientific queries
Name 56324 0
David L. Paterson
Address 56324 0
University of Queensland Centre for Clinical Research Level 8, 71/918 Royal Brisbane and Womens Hospital Herston Road Herston QLD 4029
Country 56324 0
Australia
Phone 56324 0
+61 7 3346 6074
Fax 56324 0
+61 7 3346 5598
Email 56324 0
david.antibiotics@gmail.com

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.